 Leiomyoma
"Leiomyoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
| Descriptor ID |
D007889
|
| MeSH Number(s) |
C04.557.450.590.450
|
| Concept/Terms |
Leiomyoma- Leiomyoma
- Leiomyomas
- Fibroid Tumor
- Fibroid Tumors
- Tumor, Fibroid
- Tumors, Fibroid
- Fibromyoma
- Fibromyomas
- Fibroid
- Fibroids
Fibroid Uterus- Fibroid Uterus
- Uterus, Fibroid
- Fibroma, Uterine
- Fibromas, Uterine
- Uterine Fibroma
- Uterine Fibromas
- Fibroids, Uterine
- Fibroid, Uterine
- Uterine Fibroid
- Uterine Fibroids
|
Below are MeSH descriptors whose meaning is more general than "Leiomyoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyoma".
This graph shows the total number of publications written about "Leiomyoma" by people in this website by year, and whether "Leiomyoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1988 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 2000 | 2 | 0 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 0 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 6 | 0 | 6 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 0 | 3 | | 2009 | 3 | 1 | 4 | | 2010 | 2 | 0 | 2 | | 2011 | 5 | 0 | 5 | | 2012 | 2 | 1 | 3 | | 2013 | 6 | 0 | 6 | | 2014 | 7 | 1 | 8 | | 2015 | 7 | 0 | 7 | | 2016 | 11 | 1 | 12 | | 2017 | 9 | 2 | 11 | | 2018 | 12 | 1 | 13 | | 2019 | 3 | 0 | 3 | | 2020 | 16 | 2 | 18 | | 2021 | 4 | 0 | 4 | | 2022 | 8 | 0 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Leiomyoma" by people in Profiles.
-
Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, Al-Hendy A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 Jul 13; 43(4):678-719.
-
Yang Q, Bariani MV, Falahati A, Khosh A, Lastra RR, Siblini H, Boyer TG, Al-Hendy A. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells. 2022 Jul 10; 11(14).
-
Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, Wagman RB, Al-Hendy A. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
-
Zota AR, Chu MT, Marfori CQ, Khati NJ, Al-Hendy A, Taggart T. Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.
-
Wlodarczyk M, Nowicka G, Ciebiera M, Ali M, Yang Q, Al-Hendy A. Epigenetic Regulation in Uterine Fibroids-The Role of Ten-Eleven Translocation Enzymes and Their Potential Therapeutic Application. Int J Mol Sci. 2022 Feb 28; 23(5).
-
Leyland N, Leonardi M, Murji A, Singh SS, Al-Hendy A, Bradley L. A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reprod Sci. 2022 04; 29(4):1188-1196.
-
Afrin S, Ali M, El Sabeh M, Yang Q, Al-Hendy A, Borahay MA. Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-ß3 and Wnt/ß-Catenin pathways. J Cell Mol Med. 2022 03; 26(5):1684-1698.
-
Ali M, Chen HY, Chiang YF, Badary OA, Hsia SM, Al-Hendy A. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Ali M, Raslan M, Ciebiera M, Zareba K, Al-Hendy A. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
-
Stewart EA, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg EC, Gillispie-Bell V, Imudia AN, Liu R, Kim JH, Al-Hendy A. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|